https://www.immunai.com | United States | 2018 | $292.7M
Immunai is a U.S.-based biotechnology company founded in 2018 that maps the immune system using single-cell biology and AI. The company developed the AMICA platform to gain insights into disease biology, discover novel targets, and develop effective immunotherapies. Immunai has raised significant funding, including a $215 million Series B round, and has notable individuals like CEO Noam Solomon, Robert Langer, and Jacques Banchereau on its team. The company has over 30 partnerships with academic and research institutions to advance its immune system mapping efforts.
